Introduction

San Francisco has long been recognized as a city of innovation and cultural diversity. However, like many urban centers in the United States, it faces ongoing challenges related to substance use disorders. In recent years, public health data from the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have demonstrated a national increase in overdose deaths involving synthetic opioids, particularly fentanyl. California reflects these broader trends.

In San Francisco specifically, the landscape of substance use has evolved. While opioid use disorder remains a significant concern, an increasing number of overdoses involve multiple substances. This pattern known as polysubstance use complicates treatment, increases medical risk, and requires a coordinated public health response.

This article provides a physician-level overview of polysubstance use in San Francisco, with a focus on fentanyl-related risk, overdose factors, and evidence-based recovery solutions. It also outlines how physician-led telehealth services, including DevotedDOc’s California-based treatment model, support safe and effective care for individuals with opioid use disorder.

Concerned About Fentanyl or Polysubstance Use in San Francisco?

If you or a loved one may have opioid use disorder, physician-led telehealth treatment is available across California. Early evaluation can reduce overdose risk and improve long-term recovery outcomes.

Speak With a California Physician Today

Understanding Polysubstance Use in San Francisco

What Is Polysubstance Use?

Polysubstance use refers to the concurrent or sequential use of more than one substance. This may include:

• Opioids (heroin, fentanyl, prescription opioids)
  
• Stimulants (methamphetamine, cocaine)
  
• Alcohol
  
• Benzodiazepines
  
• Sedative-hypnotics
  

In San Francisco, fentanyl has increasingly been identified not only in opioid products but also in counterfeit pills and non-opioid street drugs. This has contributed to unintentional exposure and elevated overdose risk.

Prevalent Substance Combinations and Usage Trends

Opioids and Stimulants (“Speedballing” Patterns)

One of the most concerning patterns involves combining fentanyl with stimulants such as methamphetamine or cocaine. Individuals may intentionally combine substances to balance perceived effects for example, using a stimulant to counter opioid sedation. However, this practice significantly increases cardiovascular strain and respiratory instability.

Moreover, fentanyl contamination in stimulant supplies has led to unintentional opioid exposure among individuals who do not identify as opioid users. This dramatically increases overdose risk, particularly for people without opioid tolerance.

Opioids and Benzodiazepines or Alcohol

Combining opioids with alcohol or benzodiazepines such as alprazolam or diazepam is especially dangerous. All three substances depress the central nervous system. When taken together, they can:

• Slow breathing (respiratory depression)
  
• Reduce oxygen levels
  
• Cause loss of consciousness
  
• Lead to fatal overdose
  

The CDC consistently identifies concurrent opioid and benzodiazepine use as a major risk factor for overdose death.

Why Polysubstance Overdose Is More Dangerous Than Single-Drug Overdose

From a clinical perspective, polysubstance overdoses are more complex and more difficult to reverse.

1. Respiratory Depression Is Amplified

When opioids are combined with alcohol or benzodiazepines, suppression of the brainstem respiratory center becomes more profound. Naloxone can reverse opioid effects, but it does not reverse alcohol or benzodiazepine intoxication. This complicates emergency management.

2. Cardiovascular Complications Increase

Stimulants increase heart rate and blood pressure. When combined with opioids, this can result in:

• Cardiac arrhythmias
  
• Stroke
  
• Myocardial infarction
  
• Sudden cardiac death
  

The body experiences competing depressant and stimulant effects, increasing physiological instability.

3. Delayed or Masked Symptoms

A stimulant may temporarily mask opioid sedation. Once stimulant effects diminish, severe respiratory depression may emerge unexpectedly. This delayed pattern increases fatality risk.

High-Risk Drug Combinations Require Medical Oversight

If fentanyl exposure or mixing substances has become a concern, physician-guided medication-assisted treatment can stabilize opioid dependence and lower overdose risk.

DevotedDOc provides confidential telehealth treatment for patients in San Francisco and throughout California.

• Begin Evidence-Based Treatment
  
• Schedule a Telehealth Evaluation
  
• Start Suboxone Treatment in California

Opioid and Fentanyl Trends in San Francisco

San Francisco, like many parts of California, has seen a shift from prescription opioid misuse to illicit fentanyl exposure. While prescribing practices have become more cautious over the past decade, fentanyl-related overdose deaths have increased.

Public health agencies consistently report:

• Rising fentanyl detection in toxicology reports
  
• Increasing polysubstance involvement in overdose cases
  
• Overdose events occurring across diverse demographic groups
  

Importantly, stimulant-involved overdoses often include fentanyl, even when the primary substance used was not an opioid.

Why Fentanyl Is Particularly Dangerous

Fentanyl presents unique medical risks:

High Potency

Because fentanyl is extremely potent, individuals may unknowingly consume a lethal dose. Even minimal quantity variations can cause profound respiratory depression.

Rapid Onset

Fentanyl acts quickly on opioid receptors in the brain. Respiratory suppression may occur within minutes.

Unpredictable Mixing

Illicit drug manufacturing lacks quality control. Individuals often cannot determine:

• Whether fentanyl is present
  
• The concentration
  
• Whether other depressants are included
  

This unpredictability increases overdose risk, particularly among people without opioid tolerance.

Impact on Communities and Demographics

Racial, Ethnic, and Socioeconomic Disparities

Substance use disorders affect individuals across all racial and socioeconomic groups. However, disparities exist in:

• Access to treatment
  
• Availability of naloxone
  
• Insurance coverage
  
• Stigma and discrimination
  

Communities of color may face structural barriers that delay treatment access. At the same time, overdose risk remains high among individuals experiencing poverty or unstable housing.

Addressing polysubstance use in San Francisco requires attention to equitable treatment access and culturally competent care.

The Role of Homelessness and Vulnerable Groups

San Francisco’s visible homelessness crisis intersects with substance use risk. Individuals experiencing homelessness are more likely to:

• Use substances in public or unsafe environments
  
• Lack consistent medical care
  
• Experience trauma exposure
  
• Encounter barriers to medication-assisted treatment
  

Vulnerable populations also include:

• Recently incarcerated individuals
  
• Individuals discharged from detox without follow-up care
  
• People with untreated psychiatric illness
  

Transitions in care such as release from incarceration or hospitalization are high-risk periods for overdose due to reduced tolerance.

Overdose Risk Factors

Several clinical risk factors increase the likelihood of overdose:

• Prior nonfatal overdose
  
• High-dose opioid use
  
• Concurrent benzodiazepine or alcohol use
  
• Reduced opioid tolerance after abstinence
  
• Using substances alone
  
• Chronic lung disease
  
• Liver disease
  
• Untreated opioid use disorder
  

Identifying these risk factors is critical for prevention planning.

Recovery and Treatment Solutions in San Francisco

Detox, Outpatient, and Support Services (Including San Francisco Telehealth)

San Francisco offers a range of treatment modalities:

Medical Detoxification

Supervised detox can help manage acute withdrawal symptoms. However, detox alone does not treat opioid use disorder. Without follow-up medication-assisted treatment, relapse risk remains high.

Outpatient Treatment

Outpatient programs provide:

• Medication management
  
• Behavioral therapy
  
• Case management
  
• Peer support
  

These programs allow individuals to continue working or caring for family while receiving treatment.

Telehealth-Based Treatment

Telehealth services have expanded access to care across California. Virtual visits allow patients to:

• Meet with licensed physicians remotely
  
• Initiate or continue buprenorphine treatment
  
• Receive follow-up care without transportation barriers
  

This is especially important in urban areas where clinic wait times or stigma may delay treatment.

Evidence-Based Programs and Overdose Prevention Initiatives

Effective treatment for opioid use disorder includes:

Medication-Assisted Treatment (MAT)

MAT combines FDA-approved medications with counseling and behavioral support. The most commonly used medications include:

• Buprenorphine
  
• Methadone
  
• Extended-release naltrexone
  

Buprenorphine, commonly prescribed in combination with naloxone (Suboxone), partially activates opioid receptors, reducing withdrawal and cravings while lowering overdose risk.

Naloxone Distribution

Naloxone is a life-saving medication that reverses opioid overdose. Community distribution programs are critical for reducing mortality.

Harm Reduction Strategies

Harm reduction approaches may include:

• Education about fentanyl risk
  
• Fentanyl test strips
  
• Safe use education
  
• Linkage to treatment services
  

These strategies align with public health guidance and aim to reduce preventable overdose.

How DevotedDOc Provides Telehealth Treatment in San Francisco and Across California

DevotedDOc is a physician-led telehealth clinic providing evidence-based treatment for opioid use disorder throughout California, including San Francisco and surrounding Bay Area communities.

Physician-Led Evaluation

Every patient receives:

• A comprehensive medical assessment by a licensed physician
  
• Diagnosis based on DSM-5 criteria
  
• Evaluation for co-occurring mental health conditions
  
• Assessment of overdose risk factors
  

Care plans are individualized and medically supervised.

Suboxone (Buprenorphine/Naloxone) Treatment

When clinically appropriate, buprenorphine/naloxone (Suboxone) may be initiated as part of treatment.

Management includes:

• Structured medication induction
  
• Ongoing dose adjustments
  
• Monitoring for adherence and safety
  
• Coordination with local pharmacies
  
• Follow-up virtual appointments
  

Buprenorphine reduces illicit opioid use and lowers risk of fatal overdose, even in individuals with polysubstance patterns.

Physician-Led Suboxone Treatment Available in San Francisco

DevotedDOC physicians evaluate, prescribe, and monitor medication-assisted treatment through secure telehealth visits across California.

Appointments are confidential and medically supervised.

Schedule Your First Visit

Telehealth Access Across California

Telehealth expands access to care for individuals who face:

• Transportation barriers
  
• Work schedule conflicts
  
• Housing instability
  
• Stigma concerns
  

Patients in San Francisco can attend confidential virtual visits from a secure location, without needing to wait for in-person clinic availability.

DevotedDOC provides care across the entire state of California, allowing continuity of treatment even if patients relocate within the state.

Confidential and Compliant Care

All services are delivered through secure, healthcare-compliant platforms that protect patient privacy. Importantly, these systems are designed to follow established healthcare privacy standards and safeguard sensitive medical information. For many patients, maintaining confidentiality is a critical factor when seeking care. In particular, individuals who may hesitate to pursue treatment due to stigma often place significant value on privacy and discretion.

At the same time, telehealth treatment can help reduce the visibility commonly associated with visiting in-person addiction clinics. By allowing patients to receive care from the privacy of their own home or another secure setting, telemedicine supports a more discreet treatment experience. As a result, individuals may feel more comfortable initiating and maintaining care, which can improve engagement and continuity throughout the recovery process.

Why Early Treatment Matters in Polysubstance Use

Polysubstance use increases unpredictability and overdose risk. Early physician-guided treatment can:

• Stabilize opioid dependence
  
• Reduce cravings
  
• Decrease illicit opioid exposure
  
• Lower overdose mortality
  
• Improve long-term recovery outcomes
  

Opioid use disorder is a chronic medical condition. Like other chronic illnesses, it requires structured medical management.

Conclusion

Polysubstance use in San Francisco reflects a complex intersection of fentanyl proliferation, stimulant use, mental health comorbidity, and social vulnerability. The combination of opioids with stimulants, alcohol, or benzodiazepines significantly amplifies overdose risk and complicates emergency response.

However, evidence-based treatment remains highly effective. Medication-assisted treatment with buprenorphine reduces mortality, stabilizes brain chemistry, and supports long-term recovery.

Physician-led telehealth services provided by DevotedDOc across San Francisco and throughout California significantly expand safe, confidential access to addiction care. In particular, virtual care models help reduce barriers related to transportation, stigma, and clinic availability. By combining clinical oversight, evidence-based medications, and individualized treatment planning, patients are better positioned to stabilize opioid dependence, reduce overdose risk, and begin a path toward sustainable recovery.

Importantly, early intervention can be life-saving. When individuals receive timely evaluation and appropriate treatment, the risk of overdose and long-term complications can be significantly reduced. For this reason, accessible and medically supervised treatment remains one of the most effective tools available to address polysubstance use and fentanyl-related overdose risk across California communities. Ultimately, expanding access to physician-guided care supports both individual recovery and broader public health outcomes.

Opioid Use Disorder Is Treatable. Early Care Saves Lives.

If you live in San Francisco or anywhere in California and are concerned about fentanyl or polysubstance use, physician-led telehealth treatment is available.

Medication-assisted treatment reduces overdose risk and supports long-term recovery.

Schedule a Confidential Telehealth Appointment in San Francisco and all of California

---

– DevotedDOc
Physician-Led Virtual Addiction & Reentry Care
Serving Florida,Georgia, New Mexico, Oklahoma, California, Texas and beyond.

Medically Reviewed Content

This article is intended for educational purposes and reflects guidance from national public health agencies and addiction medicine organizations. Telehealth treatment decisions are made by licensed clinicians following appropriate medical evaluation and applicable state and federal regulations.

References

U.S. Food and Drug Administration.
FDA-Approved Medications for Opioid Use Disorder.
https://www.fda.gov/drugs

Centers for Disease Control and Prevention.
Drug Overdose Deaths in the United States.
https://www.cdc.gov/overdose

Substance Abuse and Mental Health Services Administration.
Medication-Assisted Treatment (MAT).
https://www.samhsa.gov/medication-assisted-treatment

National Institute on Drug Abuse.
Polysubstance Use Facts.
https://nida.nih.gov/research-topics/polysubstance-use

California Department of Public Health.
California Overdose Surveillance Dashboard.
https://skylab.cdph.ca.gov/ODdash/

San Francisco Department of Public Health.
Overdose Prevention and Drug Trends Reports.
https://www.sfdph.org

World Health Organization.
Community Management of Opioid Overdose.
https://www.who.int/publications

U.S. Department of Health and Human Services.
Overdose Prevention Toolkit.
https://store.samhsa.gov/product/Overdose-Prevention-Toolkit

National Institutes of Health.
Buprenorphine Treatment for Opioid Use Disorder.
https://www.nih.gov

American Society of Addiction Medicine.
National Practice Guideline for the Treatment of Opioid Use Disorder.
https://www.asam.org

---